Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Looking for Drug Discovery Partnerships with Domestic Drug Makers
March 30, 2015
- Genzyme Japan Receives Approval for Japan’s 1st Oral Gaucher’s Disease Treatment Cerdelga
March 30, 2015
- E Keppra Filed for Generalized Tonic-Clonic Seizures: Otsuka, UCB Japan
March 30, 2015
- Takeda Seeks Japan Approval for Single-Packs Containing Takecab for H. pylori Eradication
March 27, 2015
- Sovaldi, Oral, Interferon-Free Treatment, Approved for Chronic HCV Infection in Japan: Gilead Sciences
March 27, 2015
- Xtandi Significantly Extends OS, Lowers Risk of Death by 23%
March 26, 2015
- Santen Ups FY2014 Financial Outlook on Merck Asset Acquisition
March 26, 2015
- Sun Pharma Completes Merger with Ranbaxy; Daiichi Sankyo Owns 9% Share in Combined Firm
March 26, 2015
- Yoshiki Ito to Lead Merged Entity of Allergan, Actavis in Japan
March 25, 2015
- 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
- Takeda to Collaborate with ImmunoGen for ADC Technology
March 25, 2015
- Investigational Duchenne Muscular Dystrophy Drug Shows Favorable Results: Nippon Shinyaku, NCNP
March 25, 2015
- AZ Looks to Lead Industry in Immuno-Oncology Arena: Oncology Head
March 24, 2015
- Opdivo Wins South Korean Approval: Ono
March 24, 2015
- Takeda to Set Up Japan Oncology, Vaccine Business Units as Part of Corporate Reorganization
March 24, 2015
- Merck KGaA Gauging Regional Priorities for PD-L1 Inhibitor Development: Exec
March 24, 2015
- Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
- Pfizer Japan Voluntarily Recalls Generic Gemcitabine
March 23, 2015
- Opicapone Reduces Off-Time by 2 Hours in Parkinson’s Disease Patients as Add-On to Levodopa: Ono
March 20, 2015
- Daiichi Sankyo, AZ to Copromote Constipation Treatment Movantik in US
March 20, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…